Trial Profile

Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal Capsules

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Temozolomide (Primary) ; Temozolomide
Indications Glioblastoma; Glioma
Focus Pharmacokinetics; Registrational
Sponsors ORPHELIA Pharma

Most Recent Events

09 Jan 2024 According to an ORPHELIA Pharma media release, an article of this study published in a Pharmaceutics.
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
31 May 2022 According to an ORPHELIA Pharma media release, data from this trial was selected by the Scientific Program Committee of the 2022 ASCO annual meeting and was released online.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com